Cachexia as a major public health problem: Frequent, costly, and deadly

Journal of Cachexia, Sarcopenia and Muscle

Volumn 4, Issue 3, 2013, Pages 173-178

  Farkas, Jerneja ^a   von Haehling, Stephan ^b   Kalantar Zadeh, Kamyar ^c   Morley, John E ^d   Anker, Stefan D ^b,e   Lainscak, Mitja ^b,f  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

^f UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

Author keywords

Cachexia; Chronic disease; Prevention; Public health

Indexed keywords

BODY COMPOSITION; BODY SIZE; BODY WEIGHT; CACHEXIA; CHRONIC DISEASE; COMMUNITY; CULTURAL ANTHROPOLOGY; ETHNIC GROUP; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84879243471     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-013-0105-y     Document Type: Review

References (39)

1. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1: 1-5.
2. Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol. 2008;101: 8-10.
3. Onwuamaegbu ME, Henein M, Coats AJ. Cachexia in malaria and heart failure: therapeutic considerations in clinical practice. Postgrad Med J. 2004;80: 642-9.
4. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121: 227-52.
5. Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2011;2: 9-25.
6. World Health Organization. The global burden of disease, 2004 update. Geneva: World Health Organization; 2008.
7. Sharma R, Anker SD. Cardiac cachexia is a world-wide problem. Int J Cardiol. 1999;71: 113-4.
8. Morley JE, Thomas DR, Wilson MMG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83: 735-43.
9. Tan BHL, Fearon KCH. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11: 400-7.
10. Evans WJ, Morley JE, Argile's J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27: 793-9.
11. von Haehling S, Lainscak M, Doehner W, Ponikowski P, Rosano G, Jordan J, et al. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle. 2010;1: 187-94.
12. Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet. 2008;371: 915-22.
13. Stewart S, Wilkinson D, Hansen C, Vaghela V, Mvungi R, McMurray J, et al. Predominance of heart failure in the Heart of Soweto Study cohort. Emerging challenges for urban African communities. Circulation. 2008;118: 2360-7.
14. Hidron AI, Gilman RH, Justiniano J, Blackstock AJ, Lafuente C, Selum W, et al. Chagas cardiomyopathy in the context of the chronic disease transition. PLoS Negl Trop Dis. 2010;4: e688.
15. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Fanelli FR. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006;42: 31-41.
16. Detels R, Breslow L. Current scope and concerns in public health. In: Detels R, McEwen J, Beaglehole R, Tanaka H, editors. Oxford textbook of public health. 4th ed. New York: Oxford University Press; 2004.
17. Saaddine JB, Narayan KM, Vinicor F. Vision loss: a public health problem? Ophthalmology. 2003;110: 253-4.
18. Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3: A57.
19. Verweij M, Dawson A. The meaning of "public" in public health. In: Dawson A, Verweij M, editors. Ethics, prevention, and public health. Oxford: Oxford University Press; 2007.
20. World Health Organization. Global status report on non-communicable diseases 2010. Geneva: World Health Organization; 2011.
21. Strong K, Mathers CD, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save? Lancet. 2005;366: 1578-82.
22. Kapiga S. Commentary: non-communicable diseases in sub-Saharan Africa: a new global health priority and opportunity. Int J Epidemiol. 2011;40: 902-3.
23. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart. 2008;94: 16-26.
24. Puska P. Non-communicable diseases - neglected diseases in global health work? Eur J Public Health. 2011;21: 269-70.
25. World Health Organization. Preventing chronic diseases: a vital investment. Geneva: World Health Organization; 2005.
26. Popkin BM, Adair LS, Ng SW. Now and then: the global nutrition transition: the pandemic of obesity in developing countries. Nutr Rev. 2012;70: 3-21.
27. Finucane MM, Stevens GA, Cowan MJ, et al. Global burden of metabolic risk factors of chronic diseases collaborating group (body mass index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9. 1 million participants. Lancet. 2011;377: 557-67.
28. Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalence. Popul Health Metr. 2012;10: 22.
29. World Health Organization. Non-communicable diseases country profiles 2011. Geneva: World Health Organization; 2011.
30. Asia Pacific Cohort Studies Collaboration. The burden of overweight and obesity in the Asia-Pacific region. Obes Rev. 2007;8: 191-6.
31. Ibrahim MM, Damasceno A. Hypertension in developing countries. Lancet. 2012;380: 611-9.
32. Yusuf S, HAwken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364: 937-52.
33. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3: e442.
34. Coats AJS, Srinivasan V, Surendran J, Chiramana H, Vangipuram SRKG, Bhatt NN, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle. 2011;2: 201-7.
35. Patel SP, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle. 2013;4: 19-29.
36. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122: 2078-88.
37. Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 2007;10: 433-42.
38. Lainscak M, von Haehling S, Doehner W, Anker SD. The obesity paradox: facts and numbers. J Cachexia Sarcopenia Muscle. 2012;3: 1-4.
39. World Health Organization. 2008-2013 Action plan for the Global strategy for the prevention and control of non-communicable diseases. Geneva: World Health Organization; 2008.